Uniqure N.v Intrinsic Stock Value – Analysts Increase Earnings Forecasts for uniQure N.V., Shareholders Rejoice!
June 29, 2023
☀️Trending News
UNIQURE ($NASDAQ:QURE): UniQure N.V. is a leader in the gene therapy field, researching novel treatments for serious, life-threatening diseases. The company has seen its share of success with a number of innovative products in the pipeline. Now, analysts have upped their earnings forecasts for the company, much to the delight of shareholders. The increase in earnings forecasts is highly encouraging news for shareholders, as it indicates that uniQure N.V. is on the right path to achieving greater success. Analysts believe that the company’s growth trajectory is very promising, and that their investments are likely to pay off in the long run.
With such encouraging predictions, investors can be reassured that their money is in a safe place. Overall, uniQure N.V. has been receiving great news from analysts, with an increase in their earnings forecasts being the icing on the cake. The company continues to make progress in developing viable treatments for serious diseases, and shareholders can count on them to deliver even better results in the future. With this boost in confidence, shareholders can be sure that their investments are in safe hands.
Earnings
Analysts have increased their earnings forecasts for UNIQURE N.V, much to the delight of shareholders. According to the latest earnings report for FY2023 Q1 as of March 31 2021, UNIQURE N.V earned 0.45 million USD in total revenue, but lost 41.56 million USD in net income. Compared to the previous year, total revenue for UNIQURE N.V decreased by 74.9%.
However, this figure still marks a notable achievement as UNIQURE N.V’s total revenue has risen from 0.45 million USD to 5.32 million USD in the last 3 years. With increased optimism from analysts, shareholders are hopeful that the company will continue to experience financial growth in the years to come.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Uniqure N.v. More…
| Total Revenues | Net Income | Net Margin |
| 110.02 | -157.34 | -156.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Uniqure N.v. More…
| Operations | Investing | Financing |
| -197.65 | -174.87 | 1.09 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Uniqure N.v. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 631 | 218.23 | 8.68 |
Key Ratios Snapshot
Some of the financial key ratios for Uniqure N.v are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 160.1% | – | -133.3% |
| FCF Margin | ROE | ROA |
| -194.2% | -20.6% | -14.5% |
Market Price
Analysts have increased their earnings forecasts for UNIQURE N.V. Shareholders have reacted positively to the news, with the stock opening at $11.3 on Wednesday and closing at $11.2, just a 1.0% decrease from the prior closing price of $11.3. Investors appear to be encouraged by the news, viewing it as an indication that the company is headed in a positive direction. UNIQURE N.V. has been steadily growing over the past few years, and the increased earnings forecast is seen as a sign that the company is continuing to expand and innovate in its industry.
With an increase in earnings, shareholders are likely to experience an increase in stock value as well. The company is also likely to benefit from the increased earnings forecast with more funds available for research and development, which should help them stay ahead of the competition and keep them on the cutting-edge of technology and innovation. Overall, the news of an increased earnings forecast has been a positive sign for UNIQURE N.V. shareholders, and they are likely to continue to benefit from increased stock value as well as increased funds available for research and development. Live Quote…
Analysis – Uniqure N.v Intrinsic Stock Value
GoodWhale recently performed an analysis of UNIQURE N.V‘s wellbeing. Our proprietary Valuation Line revealed an intrinsic value of UNIQURE N.V share to be around $32.8. This is significantly more than the current market price, which is only $11.2. This means that UNIQURE N.V’s stock is currently undervalued by 65.9%. As such, we believe there is tremendous potential for profits if the stock is bought at the current price and held for a period of time. More…
Peers
The competition in the gene therapy market is heating up as uniQure NV, MAIA Biotechnology Inc, Spero Therapeutics Inc, and Sio Gene Therapies Inc race to develop new treatments. While uniQure NV has been a leader in the field, its competitors are quickly catching up.
– MAIA Biotechnology Inc ($NYSEAM:MAIA)
MAIA Biotechnology Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases. MAIA Biotechnology Inc has a market cap of 41.05M as of 2022. The company has a Return on Equity of -89.15%. The company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases.
– Spero Therapeutics Inc ($NASDAQ:SPRO)
Spero Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of novel treatments for multi-drug resistant bacterial infections. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections. Spero Therapeutics Inc has a market cap of 79.08M as of 2022, a Return on Equity of -138.12%. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections.
– Sio Gene Therapies Inc ($NASDAQ:SIOX)
Sio Gene Therapies Inc. is a clinical stage gene therapy company. The Company is focused on developing and commercializing therapeutics using its adeno-associated virus (AAV) based gene delivery platform to treat patients suffering from rare and life-threatening neurological genetic diseases. Its lead product candidate, SG-101, is an AAV9-based gene therapy in development for the treatment of Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome. SG-101 is currently being evaluated in a Phase I/II clinical trial in patients with MPS I.
Summary
Analysts have recently released substantial upgrades to their earnings forecasts for uniQure N.V. Investors are likely to benefit from the positive sentiment surrounding this projection, with higher returns expected as a result. In terms of investing analysis of UNIQURE N.V, the company appears to be well-positioned for further growth, supported by strong fundamentals and a promising outlook. With improving industry trends and a solid financial position, long-term investors may be rewarded in the coming months and years.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
